Related Experiment Video
Updated: May 27, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Optimizing treatment for metastatic renal cell carcinoma
Jean-Jacques Patard1, Camillo Porta, John Wagstaff
1Department of Urology, University of Rennes, Rennes, France. jean-jacques.patard@bct.aphp.fr
Abstract:
With the advent of targeted antiangiogenic therapies for renal cell carcinoma (RCC), the prognosis for patients with locally advanced or metastatic disease has significantly improved. Indeed, the results of several randomized clinical trials have demonstrated that targeted therapies, such as tyrosine kinase inhibitors (TKIs), provide superior efficacy and tolerability compared with traditional cytokine-based treatments. However, TKI therapy is still associated with significant toxicities related to off-target inhibition that are detrimental to patient quality of life. The results of ongoing head-to-head trials will determine how these agents compare with each other in terms of efficacy, and whether TKIs that interact with fewer off-target kinases have improved tolerability profiles. Furthermore, examining how these agents could be integrated with surgery to provide a multimodal approach to the treatment of metastatic RCC could further improve the outlook for RCC patients.
Insights
Targeted antiangiogenic therapies, like tyrosine kinase inhibitors (TKIs), have improved renal cell carcinoma (RCC) treatment. Ongoing research aims to optimize TKI efficacy and reduce side effects for better patient outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Renal cell carcinoma (RCC) treatment has advanced with targeted antiangiogenic therapies.
- Tyrosine kinase inhibitors (TKIs) show improved efficacy and tolerability over traditional cytokine treatments for advanced RCC.
Purpose of the Study:
- To evaluate the comparative efficacy and tolerability of different TKIs in RCC treatment.
- To explore the potential of TKIs with fewer off-target effects for improved patient quality of life.
- To investigate the integration of TKIs with surgery for a multimodal approach in metastatic RCC.
Main Methods:
- Review of randomized clinical trials comparing targeted therapies with traditional treatments.
- Analysis of ongoing head-to-head trials for TKI efficacy and toxicity profiles.
- Exploration of potential multimodal treatment strategies combining TKIs and surgery.
Main Results:
- Targeted therapies, particularly TKIs, offer superior outcomes compared to cytokine-based treatments for RCC.
- TKIs are associated with significant toxicities due to off-target inhibition, impacting quality of life.
- Head-to-head trials are crucial for comparing TKI efficacy and identifying agents with better tolerability.
Conclusions:
- TKIs represent a significant advancement in managing advanced and metastatic renal cell carcinoma.
- Minimizing TKI off-target toxicities is essential for enhancing patient quality of life.
- Future research should focus on optimizing TKI selection and exploring multimodal treatment paradigms, including surgical integration, to further improve RCC patient prognosis.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers